Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral liquid for treating osteoporosis

A technology of oral liquid for osteoporosis, applied in the field of oral liquid for the treatment of osteoporosis, which can solve the problems of uncertain long-term curative effect, large toxic and side effects, and high price

Inactive Publication Date: 2009-07-22
涂平生
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, it has been found that western medicine has many disadvantages in the treatment of osteoporosis, such as large toxic and side effects, uncertain long-term curative effect, and high price. Western medicine can only prevent and delay the further development of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral liquid for treating osteoporosis
  • Oral liquid for treating osteoporosis
  • Oral liquid for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Research on the Action Mechanism of Drugs of the Present Invention on Ovariectomized Rats

[0013] 1. Selection and grouping of animals

[0014] 26 female SD rats aged 6 months were selected to undergo bilateral ovariectomy under chloral hydrate anesthesia, and 8 rats were in the sham operation group. The ovariectomized rats were divided into 8 pathological control groups, 9 estradiol groups and 9 drug treatment groups of the present invention.

[0015] 2. Prescription preparation

[0016] According to the ratio of Epimedium 12-15, Rehmannia glutinosa 15-20, Astragalus 15-20, Eucommia 15-20, Psoralen 20-30, Drynaria 20-30, soak and decoct in 20 times distilled water, and the filtrate is centrifugally concentrated Precipitate with 75% ethanol, recover ethanol; adjust pH to 7.0; add activated carbon for decolorization; make a medicinal solution containing crude drug 2g / ml. (note, following embodiment 2,3,4 also adopts same method to configure medicine of the ...

Embodiment 2

[0037] Example 2 Effects of Drugs of the Present Invention on Proliferation and Differentiation of Rat Bone Marrow Stromal Stem Cells

[0038] (1) Reagents: fetal bovine serum (product of Hangzhou Sijiqing Company), DMEM medium (product of Gibco Company in the United States), trypsin and tetramethylazozolium salt (MTT reagent is product of Sigma Company), alkaline phosphatase (product of Sigma Company), ALP) kit.

[0039] (2) Instrument: Inverted Microscope (Nikon Company), CO 2 Incubator, cell culture plate (product of Gibco, USA), 723 spectrophotometer, ELX808 microplate reader (product of BioTek, USA).

[0040] (3) Isolation and culture of MSCs: Femurs of rats were taken, and both ends were removed to flush out the bone marrow. Add 10% medium, set at 37°C, 5% CO 2 , with about (2~5)×10 4 / cm 2 Density seeded in culture flasks, placed in 5% CO 2 Cultivate in an incubator, and subculture after the cells are congested.

[0041] (4) the influence of the medicine of the p...

Embodiment 3

[0056] Example 3 The Drug of the Present Invention Antagonizes Dexamethasone to Promote the Differentiation of Bone Marrow Stromal Cells into Adipogenic Cells

[0057] (1) Isolation and culture of MSCs

[0058] After the cells were congested, they were subcultured, and the third-generation cells were used for experiments, and divided into dexamethasone (1×10 -7 mol / L) group, dexamethasone plus medicine of the present invention (80mg / L) group and matched group (conventional serum culture). Cell growth was observed under an inverted microscope.

[0059] (2) Effect of medicine of the present invention and dexamethasone on MSCs proliferation

[0060] Table 1 The influence (x ± s) of medicine of the present invention and dexamethasone on MSCs proliferation

[0061]

[0062] *p<0.05 compared with the control group, A: dexamethasone group, B: dexamethasone plus the drug group of the present invention, C: control group.

[0063] Results: MTT assay showed that dexamethasone coul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an oral liquid for treating osteoporosis, which is prepared from the following raw materials in weight ratio: 12 to 15 portions of epimedium, 15 to 20 portions of prepared rehmannia rhizome, 15 to 20 portions of Astragalus membranaceus, 15 to 20 portions of eucommia barks, 20 to 30 portions of Psoralea corylifolia, 20 to 30 portions of Davallia mariesii and proper water. The invention uses six traditional Chinese medicines, namely the epimedium, the prepared rehmannia rhizome, the Astragalus membranaceus, the eucommia barks, the Psoralea corylifolia, and the Davallia mariesii, for treating osteoporosis. The oral liquid mainly has the functions of invigorating the liver and the kidney, strengthening the muscles and bones and promoting blood circulation and stopping pain.

Description

technical field [0001] The invention relates to the technical field of medicines for treating osteoporosis, in particular to an oral liquid for treating osteoporosis. Background technique [0002] Osteoporosis is a systemic metabolic skeletal disease characterized by low bone mass and degenerative changes in bone tissue microstructure, accompanied by increased bone fragility. Bone pain and dysfunction are the most common clinical symptoms of osteoporosis, and the most serious consequence of osteoporosis is osteoporotic fracture, especially hip fracture. Once a hip fracture occurs in an osteoporotic patient, the mortality rate within one year is as high as 15%-20%, and the permanent disability rate reaches 50%, all of which will cause serious harm to individuals, families, society and the country. In the treatment of osteoporosis in Western medicine, the strongest drug that promotes bone formation by stimulating the proliferation of osteoblasts is fluoride, and most of the o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/804A61P19/10
Inventor 涂平生
Owner 涂平生
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com